Biocytocgen Pharmaceuticals (Beijing) Co. Ltd. has entered into an exclusive option and license agreement with Radiance Biopharma Inc., granting Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC).
Zymeworks Inc. has announced that its current R&D priority is to progress its differentiated portfolio of antibody-drug conjugates (ADCs) into clinical studies this year and next.
Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a worldwide collaboration and license agreement with F. Hoffmann-La Roche Ltd. for the development of YL-211, a next-generation antibody-drug conjugate candidate targeting proto-oncogene c-Met for solid tumors.
Obi Pharma Inc. has received FDA clearance for its IND application to conduct a phase I/II study of OBI-992, a novel antibody-drug conjugate (ADC) cancer therapy targeting TROP2. The trial will open shortly and aims to enroll patients with advanced solid tumors, including non-small-cell lung cancer, small-cell lung cancer and gastric cancer, although several other cancers are also potential targets.
Researchers from Mbrace Therapeutics Inc. presented the discovery and preclinical evaluation of MBRC-101, a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5, being developed for the treatment of cancer.
Inxmed Co. Ltd. has licensed Escugen’s Ezwi-Fit linker-payload platform for use in the development of next-generation tumor-associated antigen (TAA)-targeting antibody-drug conjugates (ADCs).
Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It comprises the anti-MUC18 humanized antibody pAb253-H linked to T1000 exatecan payload and showed superior antitumor efficacy than the traditional vc-MMAE-based ADC AMT-253-M.
RSS
